Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Glutamate receptor ionotropic NMDA 3B (GluN3B)** is a subunit of non-conventional N-methyl-D-aspartate receptors (NMDARs), which assemble as heterotetrameric ligand-gated cation channels primarily expressed in motor neurons. Unlike typical synaptic NMDARs, GluN3B-containing receptors exhibit low calcium permeability, reduced voltage-dependent magnesium blockade, and unique activation properties, forming complexes with GluN1 and GluN2 subunits activated by glycine (on GluN1/GluN3B) and glutamate (on GluN2), or excitatory glycinergic complexes with GluN1 alone. GluN3B contributes distinct biophysical attributes including activation, deactivation, desensitization kinetics, pH sensitivity, and interactions with allosteric modulators. Structurally, it integrates into tetrameric assemblies with domains like the amino-terminal domain (NTD), ligand-binding domain (LBD), transmembrane domain (TMD), and carboxyl-terminal domain (CTD), influencing channel gating and ion selectivity. In disease contexts, GluN3B plays roles in calcium mobilization into mitochondria and may contribute to neurodegenerative processes through dominant negative effects on NMDAR function. While not prominently linked to approved drugs, its modulation alters synaptic plasticity and could pose therapeutic challenges due to subdued calcium signaling compared to canonical GluN2-containing NMDARs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic NMDA 3B (GluN3B).